Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 10/20 | 0.43 |
| ▸ | CDK2 | P24941 | 10/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 10/20 | 0.43 |
| ▸ | IKBKB | O14920 | 10/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | PIK3R5 | Q8WYR1 | 1/20 | 0.41 |
| ▸ | PIK3R3 | Q92569 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5326432 | 0.88 | CCNA2 (0.47) | CCNA2CDK2CCNA1PIK3CDPIK3R2 | |
| SCHEMBL5253419 | 0.86 | CCNA2 (0.46) | CCNA2CDK2CCNA1IKBKB | |
| SCHEMBL14532705 | 0.84 | CCNA2 (0.53) | CCNA2CDK2CCNA1IKBKBPIK3CD | |
| SCHEMBL5335359 | 0.82 | CCNA2 (0.58) | CCNA2CDK2CCNA1IKBKB | |
| SCHEMBL5336498 | 0.82 | IKBKB (0.53) | IKBKB | |
| SCHEMBL5342584 | 0.81 | CCNA2 (0.59) | CCNA2CDK2CCNA1IKBKB | |
| SCHEMBL14558116 | 0.81 | IKBKB (0.48) | CCNA2CDK2CCNA1IKBKBPIK3CD | |
| SCHEMBL6658045 | 0.80 | CCNA2 (0.46) | CCNA2CDK2CCNA1IKBKB | |
| SCHEMBL5339586 | 0.79 | IKBKB (0.45) | CCNA2CDK2CCNA1IKBKB | |
| SCHEMBL5344937 | 0.79 | IKBKB (0.47) | CCNA2CDK2CCNA1IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2009029808-A | SUBSTITUTED PYRAZOLYL COMPOUND FOR TREATING INFLAMMATION | PHARMACIA CORP | 2009-02-12 | — | — | JP | disclosed |
| EP-1427706-B1 | SUBSTITUTED PYRAZOLO COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORP (US) | 2007-05-30 | — | — | EP | disclosed |
| US-7211597-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2007-05-01 | — | — | US | disclosed |
| US-7186743-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186743-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-20050256180-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | BERGMANIS ARIJA A | 2005-11-17 | — | — | US | disclosed |
| US-6956052-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2005-10-18 | — | — | US | disclosed |
| EP-1501805-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2005-02-02 | — | — | EP | disclosed |
| US-6849653-B2 | 1H-benzo(g)indazole compounds as anticarcinogenic agents and also treat arthritis | PHARMACIA CORPORATION (US) | 2005-02-01 | — | — | US | disclosed |
| EP-1476431-A1 | TRICYCLIC PYRAZOLE DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2004-11-17 | — | — | EP | disclosed |
| EP-1438293-A2 | SUBSTITUTED PYRAZOLYL BENZENESULFAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2004-07-21 | — | — | EP | disclosed |
| EP-1427706-A1 | SUBSTITUTED PYRAZOLO COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20040110741-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORARTION | 2004-06-10 | — | — | US | disclosed |
| WO-2003095430-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2003-11-20 | — | — | WO | disclosed |
| WO-2003070706-A1 | TRICYCLIC PYRAZOLE DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20030125361-A1 | Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2003-07-03 | — | — | US | disclosed |
| US-20030114432-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2003-06-19 | — | — | US | disclosed |
| WO-2003027075-A2 | SUBSTITUTED PYRAZOLYL BENZENESULFAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003024935-A2 | SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2003-03-27 | — | — | WO | disclosed |
| WO-2003024936-A1 | SUBSTITUTED PYRAZOLO COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114432-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | IRAK4, IL1B, IRAK2 | CCNA2 2589/4885CDK2 392/4885CCNA1 2090/4885 |
| US-20040110741-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | IRAK4, IL1B, IRAK2 | CCNA2 2589/4885CDK2 392/4885CCNA1 2090/4885 |
| US-20030125361-A1 | Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation | IRAK4, NLRP3, CXCL8 | CCNA2 2104/4885CDK2 372/4885CCNA1 1547/4885 |
| US-20050256180-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | IRAK4, IL1B, IRAK2 | CCNA2 2589/4885CDK2 392/4885CCNA1 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.